Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD

Respiratory Medicine

Volumn 93, Issue 12, 1999, Pages 909-911

  Cazzola, M ^a,c   Matera, M G ^b   Di Perna, F ^a   Califano, C ^a   D'Amato, M ^a   Mazzarella, G ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; OXITROPIUM BROMIDE;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0033404361     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90058-6     Document Type: Article

References (13)

1. Cazzola M, Spina D, Matera MG. The use of bronchodilators in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1997; 10: 129-144.
2. 2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med 1999; 93: 227-229.
3. 2-agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999; 54: 730-736.
4. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995; 8: 267-271.
5. Cazzola M, Matera MG, Di Perna F, et al. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 354-357.
6. Cazzola M, Matera MG, Di Perna F, et al. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Eur Respir J 1998; 12 (Suppl 28): ls.
7. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497-499.
8. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62-66.
9. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S72-S120.
10. Maesen FP. Eformoterol versus salbutamol in patients with ROAD. Br J Clin Pract 1995; (Suppl 81): 8-10.
11. Peel ET, Anderson G. A dose response study of oxitropium bromide in chronic bronchitis. Thorax 1984; 39: 453-456.
12. Lal S, Eyre-Brook A, Mitra SK, et al. Oxitropium bromide in chronic bronchitis. Res Clin Forums 1991; 13 (No. 2, part 2): 29-36.
13. Skorodin MS, Gross NJ, Moritz T, et al. Oxitropium bromide, a new anticholinergic bronchodilator. Ann Allergy 1986; 56: 229-232.